Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02102802 · ClinicalTrials.gov registry record
Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD
A clinical trial, sponsored by Resilient Pharmaceuticals.
- Completed
- Registry status
- 10
- Enrollment target
NCT02102802: Completed study, sponsored by Resilient Pharmaceuticals.
NCT02102802 is a clinical trial that has completed, run by Resilient Pharmaceuticals. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02102802 has completed, sponsored by Resilient Pharmaceuticals.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The goal of this observational sub-study is to provide information on how MDMA-assisted therapy affects the brain and body of people with chronic PTSD. The main question it aims to answer is: Is PTSD symptom reduction associated with changes in heart rate variability and brain activity? Participants from the MP-8 study will be invited to enroll in this sub-study where they will undergo an fMRI brain scan and other measurements of body function.
Primary Outcome
Brain activity measured via functional magnetic resonance imaging (fMRI) after listening to trauma-related scripts.
Interventions
- DRUG Midomafetamine
- BEHAVIORAL Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-08-03 |
What the finished NCT02102802 record still lists
NCT02102802 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Midomafetamine is the first listed.
NCT02102802 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02102802 about?
NCT02102802 is a clinical study titled "Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD". The goal of this observational sub-study is to provide information on how MDMA-assisted therapy affects the brain and body of people with chronic PTSD. The main question it aims to answer is: Is PTSD symptom reduction associated with changes in heart rate variability and brain activity? Participan...
What is the current status of trial NCT02102802?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2014-01. Estimated completion is 2015-08-03.
What interventions are being tested in trial NCT02102802?
The interventions under investigation include: Midomafetamine (DRUG), Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02102802?
This trial is sponsored by Resilient Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia